Physiology comes first
Every decision is evaluated by its contribution to integrated physiological function and homeostasis.
Biotechnology · Physiology · Molecular botanical therapeutics
Molecular therapeutic solutions built around physiology.
Sonda Pharma integrates analytical science, systems physiology, therapeutic modulation and responsible biotechnology to transform natural molecular diversity into reproducible, evidence-based therapeutic opportunities.
Sonda PharmaPhysiology · Reproducibility · Translation
Why we exist
A company built around a scientific method, not a single molecule.
Sonda Pharma’s scientific foundations predate the company. A personal clinical circumstance brought specialist knowledge into direct contact with a real patient need. That experience was never treated as evidence of efficacy: it created a responsibility to investigate a biologically rational hypothesis rigorously and, if validated, make it available to others.
Founded in 2021, Sonda Pharma is the organisational infrastructure through which biological knowledge, analytical precision and responsibility towards patients can become reproducible therapeutic innovation.
“Scientific knowledge achieves its greatest value when it becomes a real opportunity for patients.”
Our DNA
Principles that remain while products and technologies evolve.
Sonda Pharma is defined not by today’s product, but by the criteria through which tomorrow’s decisions will be made.
Biology before technology
Technology is adopted only when it serves the biological objective and preserves molecular integrity.
Respect complexity
Living systems should not be simplified beyond what scientific understanding justifies.
Prefer modulation
Whenever appropriate, we support the recovery of regulation rather than replacing it indiscriminately.
Practise scientific humility
Every hypothesis remains open to revision and every statement must be proportionate to the evidence.
Patients give purpose
Research is complete only when credible knowledge can become a responsible opportunity.
The scientific challenge
Botanical identity does not guarantee biological identity.
Plants continuously adapt their metabolism to the environment. Climate, altitude, season, soil and biological stress can alter the molecules produced even within the same species.
To make botanical therapeutics reproducible, the molecular compositions that are genuinely relevant to human physiology must be identified, characterised and validated. The objective is not merely to standardise production. It is to reproduce biological function.
PDF
The Scientific Foundations of Sonda Pharma · Version 2.0
Complete publication in English · 26 pages
Open or download the documentA complementary position
Not replacing modern medicine. Expanding the questions therapeutic research can ask.
Sonda Pharma recognises the decisive value of modern pharmacology. Its position is complementary: in conditions characterised by chronic dysregulation, how can innovation support the recovery of physiological regulation while allowing the organism to remain an active participant?
Modulation is not an alternative to conventional pharmacology. It is an additional strategy when the underlying issue is persistent, excessive or maladaptive activity rather than the complete absence of a function.
Scientific platform
Discovery begins with a biological question, not a molecule.
The platform connects physiology, molecular selection, analytical characterisation, biological validation, manufacturing strategy and clinical translation within one development sequence.
1
Understand physiology
Define the physiological process and how its regulation has been altered.
2
Define the biological question
Establish the question before selecting molecules, technologies or products.
3
Identify relevant compositions
Biological relevance cannot be inferred from analytical abundance alone.
4
Characterise with precision
Identity, concentration, stability, analytical fingerprint and reproducibility.
5
Define concentration and purification
Determine the degree of compositional control required for valid study.
6
Validate function in context
Study the effective composition at exposures and in models coherent with the objective.
7
Select the manufacturing strategy
Cultivation, extraction, plant cells or other technologies are chosen according to biology.
8
Develop a reproducible system
The formulation is the consequence of understanding, not the starting point.
9
Translate evidence into clinical application
Knowledge becomes a therapeutic programme through proportionate, verifiable evidence.
Lead programme
GastroNYX: the first concrete expression of the platform.
A molecular programme supported by an international patent application and focused on modulating inflammatory processes associated with gastric disorders, lesions or diseases.
Field
Gastric inflammation and mucosal damage
Current status
Implemented as a food supplement
Intellectual property
PCT/IB2025/050183 · WO2025/153918 A1
Molecular architecture
Phenylethanoid glycosides and defined combinations
Formulation
Mucilages and multiple dosage forms
Objective
Prospective analytical, biological and clinical validation
What is documented
Protected architecture and operational implementation.
- International application filed on 8 January 2025 and published as WO2025/153918 A1.
- Formulations comprising one or more phenylethanoid glycosides.
- Preferred combinations, including verbascoside and lamiuside-A in defined ratios.
- Formulation, manufacturing, distribution and customer-support experience generated through market presence.
What remains to be established
Clinical validation is the next value-creating step.
- Analytical specifications and batch-to-batch fingerprints suitable for advanced development.
- Mechanistic validation of the actual formulation.
- Dose, duration, population and clinical positioning.
- Controlled clinical efficacy and a safety profile for any future medicinal pathway.
Claims boundary. GastroNYX is not presented as a cure for gastro-oesophageal reflux disease, as a clinically proven therapy or as a product with an established pharmaceutical safety profile. Commercial experience and reported observations may generate hypotheses, but they do not replace prospective controlled studies.
Results achieved
Concrete progress. Declared limitations. Measurable next steps.
Sonda Pharma clearly distinguishes documented facts, research-generating signals and future objectives. Communication should never move faster than the evidence.
Company established
Italian innovative start-up with a presence in Milan and Trento.
Translation into market
The formulation concept has been translated into consumer-health products manufactured, distributed and supported through OsaNYX.
International application
PCT/IB2025/050183, filed on 8 January 2025 and published as WO2025/153918 A1.
Operational experience
Manufacturing, quality, logistics, commercial channels and customer care have generated concrete industrial learning.
Formalised method
Scientific principles and the development sequence are defined within a coherent framework independent of the lead asset.
Ready for dialogue
Scientific, IP, CMC and development materials are organised for qualified counterparties and due diligence.
Evidence maturity
Three levels that must not be confused.
Structure, formulation and IP
An implemented formulation, manufacturing documentation, a published PCT application and commercial activity exist.
Historical and commercial experience
Prior research and customer feedback may inform models, endpoints and priorities. They do not establish causality or efficacy.
Controlled clinical efficacy
No prospective controlled evidence package is yet available to support therapeutic claims or a medicinal profile.
Next steps
Convert a protected hypothesis into a validated asset.
A defined test article, analytical and functional reproducibility, formulation-specific mechanism, a clinical-regulatory pathway and prospective evidence generation.
Partners and investors
Partners able to accelerate evidence, development and access without diluting scientific coherence.
The ideal collaboration brings complementary capabilities in quality and CMC, mechanism, clinical development, regulatory strategy, manufacturing, intellectual property, international markets or strategic capital.
Rx
Pharma and phytopharma
Co-development, regional or field-of-use licensing, regulatory and clinical strategy, manufacturing and commercialisation.
U
Universities and research
Mechanistic biology, analytical characterisation, plant biotechnology and translational research.
+
Clinicians and hospitals
Protocol design, feasibility, endpoints, patient pathways and investigator-led collaborations.
€
Strategic investors
Capital and expertise aligned with clinical, IP and organisational inflection points.
Potential structures
A flexible model with clear responsibilities.
Confidential information is shared with qualified counterparties under an appropriate confidentiality agreement.
Objective of the first discussion: define the question, test strategic alignment, identify the information required and agree realistic responsibilities and timelines.
General contact
info@sondapharma.com
For corporate, scientific, clinical, industrial and investment enquiries.
Contact Sonda PharmaProducts and purchases
OsaNYX
For the catalogue of products already developed, commercial information and online purchases, visit the official shop.
Visit osanyx.it ↗Founded
2021
Milan
Piazza IV Novembre 4 · 20124
Trento
Via alla Veduta 84 · 38121
Scientific and medical disclaimer
The information is provided for corporate and scientific communication. It does not constitute medical advice, does not replace consultation with a healthcare professional and must not be interpreted as a claim of clinical efficacy or regulatory approval.
Intellectual-property status
WO2025/153918 A1 concerns a published international application. A PCT publication is not an internationally granted patent. Any territorial rights depend on national or regional entry, examination and grant.
Privacy
This static version does not install profiling cookies, use analytics or submit form data to a server. The form prepares a message in the user’s email application.